- Home
- HAFN vs QURE Comparison
HAFN vs QURE Comparison
Compare HAFN & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | QURE |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | Singapore | Netherlands |
| Employees | N/A | 248 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HAFN | QURE |
|---|---|---|
| Price | $10.52 | $22.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $11.50 | ★ $61.24 |
| AVG Volume (30 Days) | ★ 3.0M | 2.5M |
| Earning Date | 11-18-2026 | 11-09-2026 |
| Dividend Yield | ★ 10.76% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $54.78 |
| Revenue Next Year | N/A | $356.14 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.17 | $8.73 |
| 52 Week High | $11.10 | $71.50 |
Technical Indicators
Market Signals| Indicator | HAFN | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 28.08 |
| Support Level | $8.45 | $22.32 |
| Resistance Level | $11.10 | $25.61 |
| Average True Range (ATR) | 0.35 | 1.19 |
| MACD | -0.06 | 0.75 |
| Stochastic Oscillator | 55.81 | 57.58 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.